Clinical trial · Observational
Prevalence of Oral Side Effects Associated With Chemo and Radiotherapy for Treating Head and Neck Cancer
Prevalence of Oral Side Effects Associated With Chemo and Radiotherapy for Treating Head and Neck Cancer: a Cross-sectional Study
NCT04845854CI-TRIAL-00063923completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A cross-sectional study will be conducted to report oral complications during chemo and radiotherapy treatment in case of patients diagnosed with head and neck cancer and the effect of theses oral side effects on patients' quality of life which will in turn allow the implication of preventive measures
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Complications of Chemotherapy and Head and Neck Radiation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- by ESAS questionnaire ,clinical examination of the patient
- timeFrame
- through study completion, an average of 1 year
- description
- questionnaire is answered by the patient
- measure
- oral mucositis assessed by WHO(world Health Organization) scale, clinical examination
- timeFrame
- through study completion, an average of 1 year
- description
- grade(A)none , (I)mild ,(II)moderate (III)severe and( life threatening (B) 1 asymptomatic or mild pain,2moderate,3 severe,4 life threatening
- measure
- xerostomia by CODs (Clinical oral dryness scale)
- timeFrame
- through study completion, an average of 1 year
- description
- questionnaire completed with added clinical examination scored from 1-3indicate mild dryness then 4-6 moderate dryness and 8-10 severe dryness
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients after the first week of their treatment till the end of their treatment protocol and at their follow-up visits * patients who completed ESAS questioner * Male and female patients from 20 -70 years old who are diagnosed with head and neck cancer. Exclusion Criteria: * Patients who didn't start their treatment before the examination * Patients who refuse to participate in the study. * Patients with leukemia or blood cell cancers, infants and children
References
Publications (0)
Data not yet available
No reference posted for this study.